CAI vs STT · rev $812.0M vs P/E 17, rev $7.84B
Caris Life Sciences, Inc. Common Stock (CAI) versus State Street Corp (STT) — a side-by-side from cached financials, not a winner call.
Caris Life Sciences, Inc. Common Stock (CAI) is a biotechnology company listed on NASDAQ.
State Street Corp (STT) is a asset management company listed on US.
Latest reported CAI revenue for 2025-12-31 was $812.0M. Net income was -$68.1M. Revenue was up 97.0% from 2024-12-31 to 2025-12-31. CAI currently screens at market cap $5.22B.
Latest reported STT revenue for 2026-06-30 was $7.84B. Net income was $1.85B. STT currently screens at market cap $45.02B and trailing P/E 16.5.
CAI currently screens at market cap $5.22B. STT currently screens at market cap $45.02B and trailing P/E 16.5.
Not investment advice. Open the CAI and STT stock pages for the full models.
Not investment advice.